China- 2 NRS about the same deal#1 first- copied and pasted from website before taken down...and then the replacent NR. Different to say the least:
Huaxipharm has signed a letter of intention agreement with Sirona Biochem Corp, a listed company registered under Canadian law and listed on the Toronto stock exchange (hereinafter referred to as "SIRONA"). Sirona and its French subsidiary TFChem SAS expressed their willingness to cooperate strategically with Huaxipharm. Sirona and Huaxipharm will actively explore various cooperation modes, including contract research, contract manufacturing as well as licensing, with a view to reaching an international cooperation development agreement between the two companies. The collaboration will involve patented novel compounds created by Sirona, including compounds with potential effects on cell preservation, anti-aging, anti-wrinkle and anti-diabetes, and is expected to bring significant benefits to both companies. Sirona is also interested in a possible collaboration with the skin whitening agent TFC-1067. Sirona believes that its fluorochemical platform, background and position in the industry, coupled with proven success and trading flexibility, make it an excellent partner of Huaxipharm. Sirona has the ability and commitment to work with the Huaxipharm team and hopes to leverage Huaxipharm's core competencies and experience in large-scale pharmaceutical chemical synthesis and formulation to realize Sirona's vision of delivering novel therapies in the healthcare and cosmetics industries. Huaxipharm has signed a Letter of Intent (“LOI”) with Sirona Biochem Corp, a listed company registered under Canadian law and listed on the Toronto stock exchange Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”). Sirona has expressed their willingness to cooperate strategically with Huaxipharm. Sirona and Huaxipharm will actively explore various cooperation modes, including contract research, contract manufacturing as well as licensing, with a view to reaching an international cooperation development agreement between the two companies. The collaboration will involve on all steps to complete full commercialization of the products created by Sirona. This includes preclinical, clinical development, regulatory, commercial scale up and manufacturing for commercial applications of Sirona’s compounds for indications mutually agreed upon in the definitive agreement.
Sirona Biochem is a drug and cosmetic ingredient discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Sirona believes that its new drug discovery platform, coupled with proven success and trading flexibility, make it an excellent partner of Huaxipharm. Sirona has the ability and commitment to work with the Huaxipharm team and hopes to leverage Huaxipharm's core competencies and experience in large-scale pharmaceutical chemical synthesis and formulation to realize the common visions of Huaxipharm and Sirona in delivering novel therapies in the healthcare and cosmetics industries.